Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma
Last Updated: Thursday, February 10, 2022
Based on an analysis of mutations and phospho-ERK levels in tumor samples from patients with relapsed/refractory DLBCL, researchers believe there may be a role for RAS guanyl releasing protein 4 (RASGRP4) mutations in B-cell malignancies. Data show that 33% of tumors gained p-ERK expression, when comparing diagnostic and relapsed specimens, suggesting promotion of survival.
Advertisement
News & Literature Highlights
